Translumina Therapeutics starts direct UAE operations to tap into the region’s coronary stents market
Translumina's entry into the UAE aligns with the country’s push to enhance its medical infrastructure. The UAE healthcare sector has been steadily growing, with particular emphasis on improving specialized treatments such as cardiac care. The company brings a comprehensive portfolio of drug-eluting stents (DES) and bioresorbable scaffolds, products that have been highly regarded in both the domestic and international markets. Known for its high clinical success rates, Translumina’s products could help hospitals and clinics in the UAE offer world-class cardiac treatments.
This expansion comes at a time when the UAE is striving to reduce its reliance on imported healthcare technologies and services. As one of the region’s fastest-growing markets for medical devices, particularly in cardiovascular care, the entry of Translumina directly into the UAE market could reduce the lead times for access to advanced technologies and reduce costs by eliminating the need for middlemen. Translumina has been expanding globally, and this new development underscores its efforts to become a key player in not just India but the broader global healthcare landscape.
Cardiovascular health remains a critical concern for the UAE government. As per the World Health Organization (WHO), lifestyle-related ailments like heart disease are among the leading causes of death in the region. With the prevalence of risk factors such as obesity, diabetes, and high blood pressure, cardiac interventions are frequently required, placing pressure on healthcare providers to offer cutting-edge solutions.
Translumina has been focusing on developing stents that not only deliver life-saving technology but also emphasize patient safety and long-term health outcomes. Its partnership with major hospitals in India, such as the All India Institute of Medical Sciences (AIIMS), has helped the company demonstrate the efficacy of its technologies in high-risk patients. Its stents are made using the latest design innovations and materials, allowing for greater efficacy and reduced chances of post-surgical complications.
The UAE market for coronary stents has traditionally been served by multinational corporations. However, the entry of Translumina with its locally-driven operations marks a significant shift towards a more competitive landscape. This development is likely to bring about cost benefits, which could be passed on to both healthcare providers and patients. For hospitals that have relied on overseas imports for their cardiovascular treatment devices, the ability to source these products domestically from a company with a solid track record offers a new level of convenience.
This expansion is just the latest in a series of milestones for Translumina Therapeutics, which has continued to secure its place in both emerging and mature markets globally. After solidifying its leadership in the Indian coronary stents market, the company has been expanding into Europe and other parts of Asia. In recent years, Translumina's products have been used in several high-profile cardiovascular interventions worldwide, demonstrating their reliability and efficacy.
The UAE offers a strategic location for Translumina to serve the broader Middle Eastern and North African (MENA) region. By establishing a direct presence in Dubai, the company positions itself at a crossroads for trade and medical services, giving it easy access to neighboring markets. Dubai’s reputation as a hub for medical tourism could also benefit the company's growth strategy, as more patients from across the region seek advanced cardiac care in the UAE.
As healthcare spending continues to rise across the GCC countries, companies like Translumina are poised to benefit from a burgeoning market. The UAE government has also been supportive of initiatives that bring international expertise into the local healthcare sector, as part of its long-term vision to develop world-class medical facilities. Translumina’s direct entry into the UAE market is expected to reinforce this vision, providing patients and medical professionals with access to the latest cardiovascular technologies.
By initiating direct operations in the UAE, Translumina Therapeutics seeks to offer more than just coronary stents. Its comprehensive approach includes training programs for local surgeons and medical professionals, aimed at ensuring that the devices are used to their maximum potential and that patients receive the best care possible. The company’s focus on education and long-term relationships with healthcare providers demonstrates its commitment to improving cardiac care outcomes in the region.
Join the conversation